It would be more meaningful to have a discussion about context and why a price would go up or down instead of depending on the 'tried-and-true' gap will be filled because it will.
That isn't much different than saying the price will rise because there are important catalysts in Sept.
I think the market is seeing that CLSN is under-valued, with respect to some peers in Biotech, eg KERX OREX.
If something is viewed as being under-valued, it has a difficult time selling off big, especially when time is getting short for potential big breaking news. People will be there to catch the sell-off, if it comes, more-so than they would have several months ago.
You say you won't buy in until 3.60, you might be right, we shall see, I'll buy some there with you.